All articles by GBI Research

GBI Research

HPV vaccines continue to dominate cancer vaccines landscape

Cancer vaccines are a type of immunotherapy used to either treat existing cancer or prevent the development of cancer.

The bioterrorism threat: what power can terrorists wield with microbes?

Infectious diseases kill over 17 million people yearly and the agents that cause them are toxic, widespread and reproducible. These factors make biological organisms a potential weapon for terrorists.

GM babies: He Jiankui and the ethics of gene editing

In late November, Shenzhan’s Southern University of Science and Technology researcher He Jiankui announced on YouTube that his research had resulted in the birth of the first genetically modified children.

‘Nanocarrier’ brings hope for disease-modifying osteoarthritis drugs

Osteoarthritis is a progressive degenerative disease of the joints thought to affect over 30 million adults in the US.

Industry experts believe External Reference Pricing is coming to the US

External Reference Pricing is the practice of using the price of a product in foreign countries to derive a benchmark for setting or negotiating the price of a product within a specific country.

Scorpion venom could hold the key to breaching the blood-brain barrier

The Peptides and Proteins Lab at the Institute for Research in Biomedicine has discovered the capacity of a small protein, found in scorpion venom, to carry drugs across the blood–brain barrier.

Waste not, want not: how exosomes went from trash to trials

Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid (CSF) and cultured medium of cell cultures in vitro.

Does psychedelic microdosing have true potential in mental health?

Micro-dosing is a growing health phenomenon involving the regular consumption of small doses of psychedelic drugs, usually a tenth of that used for recreational use, so that they do not experience a full-body response, but enough to initiate a response on a cellular level. 

Xofluza: prospects for the first FDA-approved flu therapy in 20 years

On October 20 2018, Xofluza (baloxavir marboxil) became the first medicine to achieve FDA approval for the treatment of the influenza virus, better known as ‘the flu’, in 20 years.

Will biosimilar launches send Humira tumbling in Europe?

Last week, the EU saw the launch of four different biosimilars of Humira (adalimumab), the best-selling prescription drug in the world; Sandoz’s Hyrimoz, Amgen’s Amgevita, Samsung Bioepis’s Imraldi and Mylan’s Hulio.